Other Novel PET Radiotracers for Breast Cancer

The Current and Future Roles of Precision Oncology in Advanced Breast Cancer

“…As previously discussed, PARP inhibitors are efficacious in patients with metastatic HER2-negative breast cancer with germline BRCA1 and BRCA2 mutations (28). Several PARP-targeting agents have been radiolabeled (66,67). In early-phase clinical trials, 18 F-fluorthanatrace uptake in tumors was variable but correlated with PARP-1 expression.…”

“…Stromal cancer-associated fibroblasts and tumor-associated macrophages express fibroblast activation protein in all breast cancer subtypes (75). Early studies of FAPI PET/CT in breast cancer were generally small, used different FAPI radiotracers, and included heterogeneous subtypes of breast cancer but consistently demonstrated increased FAPI uptake and tumor-to-background ratios in primary breast cancer, lymph node metastases, and bone metastases compared with 18 F-FDG (66,76). FAPI PET/CT appears advantageous for detecting smaller lesions and those breast cancers with low-level 18 F-FDG uptake (77).…”